DHA makes up ~97% of omega-3 fat in the brain. Here's an honest read of the connectivity, grey matter, and dosing evidence, no hype.
From this read
DHA, the omega-3 fatty acid that makes up roughly 97% of the omega-3 fat in your brain, is one of the few nutrients where the structural argument for supplementation is genuinely hard to dismiss. A 2020 neuroimaging study found that higher plasma omega-3 levels correlated with measurably stronger functional brain connectivity across multiple networks. That's not a trivial finding. But the cognitive performance story is more complicated than most supplement marketing lets on.
What the evidence actually shows
I want to be straight with you: the omega-3 and brain literature is large, uneven, and often misrepresented. There are studies with real signal. There are also meta-analyses that show negligible effects in already-healthy populations. Both things are true simultaneously, and pretending otherwise would be dishonest.
Start with connectivity. Talukdar et al. (2020) used resting-state fMRI in a mixed-age sample and found that individuals with higher omega-3 PUFA biomarker levels showed significantly stronger functional connectivity in the default mode network and frontoparietal network, two systems closely linked to memory consolidation and executive function. This was an observational design, so causality isn't established, but the biological plausibility is there.
On brain structure, Macaron et al. (2021) reviewed associations between omega-3 status and brain morphology in cognitively healthy older adults. Higher DHA and EPA levels were associated with greater grey matter volume in regions including the hippocampus and prefrontal cortex, areas that tend to shrink with age. Again, observational. But the consistency across studies in that review is worth noting.
The systematic review by Derbyshire (2018) looked at omega-3 supplementation across the lifespan and found the most consistent evidence in two populations: developing brains (foetal through early childhood) and older adults showing early cognitive decline. In healthy middle-aged adults with adequate dietary intake, the effect sizes were smaller and less consistent. That's an honest read of the data.
What's biologically happening: DHA, membranes, and microglia
DHA isn't just a passenger in brain tissue, it's a structural component. Around 60% of the brain's dry weight is fat, and DHA is the dominant polyunsaturated fatty acid in neuronal membranes. Its long, flexible carbon chain (22 carbons, 6 double bonds) keeps cell membranes fluid at physiological temperatures. That fluidity directly affects how efficiently ion channels open and close, how readily neurotransmitter receptors move laterally in the membrane, and how fast signal transduction cascades can run.
Calder (2017) provides a detailed account of DHA's roles: beyond membrane structure, DHA is a precursor to specialised pro-resolving mediators, lipid molecules including resolvins and protectins, that may help regulate the resolution of neuroinflammatory processes. This matters because chronic low-grade neuroinflammation is increasingly implicated in age-related cognitive decline.
There's also an interesting microglial angle. Madore et al. (2020) showed in mouse models that omega-3 fatty acids tune microglial phagocytosis of synaptic elements during brain development, essentially, how aggressively the brain's immune cells prune synapses. Omega-3 deficiency in that study was associated with excessive synaptic pruning. The human translation is uncertain, but the mechanism is plausible and worth tracking.
EPA plays a different role. Where DHA is predominantly structural, EPA appears to act more at the signalling level, particularly in modulating inflammatory eicosanoid pathways. Deckelbaum et al. (2021) make the case that EPA and DHA may need to be considered separately rather than as an interchangeable pair, with DHA being the primary target for brain-specific outcomes. That distinction matters when choosing a supplement.
Dosing: what the clinical evidence actually supports
Most of the RCTs showing cognitive or structural effects used combined EPA+DHA doses in the range of 1,000, 2,000 mg per day, with DHA typically comprising 500, 1,000 mg of that total. Studies in older adults with mild cognitive concerns have used doses as high as 2,000 mg DHA alone.
The BDNF data is relevant here. Paduchová et al. (2021) examined the effect of omega-3 supplementation on brain-derived neurotrophic factor (BDNF), a protein involved in neuronal survival and plasticity, alongside homocysteine and thromboxane in a depressed population. Supplementation at approximately 2,000 mg EPA+DHA per day was associated with measurable changes in BDNF levels and homocysteine, though this was a specific clinical population and the findings may not generalise directly to healthy adults.
For the UK market specifically, most fish oil products deliver 300, 600 mg EPA+DHA per capsule, meaning you'd need 3, 5 capsules daily to reach the doses used in the strongest studies. That's worth knowing before buying a single-capsule product and expecting clinical-level effects.
Algal DHA is the form I chose for the KōJō Daily Formula, not fish oil. The reason is simple: algae is the original source (fish accumulate DHA by eating algae), it avoids the oxidation issues that plague poorly stored fish oil, and it's appropriate for people who don't eat fish. Algal DHA has comparable bioavailability to fish-derived DHA in the published literature.
DHA versus EPA: does the distinction matter for the brain?
Yes, and the supplement industry mostly ignores this. The majority of fish oil products are EPA-heavy, often in a 3:2 or even 5:1 EPA:DHA ratio, because EPA is cheaper to concentrate and the cardiovascular literature has historically focused on EPA.
For brain-specific outcomes, the evidence points more strongly toward DHA. As Deckelbaum et al. (2021) note, DHA is selectively incorporated into brain phospholipids at a rate roughly 20 times higher than EPA. The brain actively takes up DHA via a specific transport mechanism at the blood-brain barrier. EPA crosses less readily and is rapidly beta-oxidised for energy once inside the brain, it doesn't accumulate in neural tissue the way DHA does.
EPA isn't irrelevant to brain health. The signalling and anti-inflammatory roles of EPA-derived mediators do affect neuroinflammation. But if you're buying a supplement specifically for cognitive support, a DHA-led or DHA-only formula makes more biological sense than a generic high-EPA fish oil.
Omega-3 and the ageing brain: where the evidence is strongest
The most consistent human evidence for omega-3 brain effects comes from studies in older populations and women at midlife. Minihane (2025) published a detailed review on omega-3 fatty acids, brain health, and the menopause, a population where oestrogen decline may interact with DHA metabolism, potentially increasing the brain's vulnerability to DHA insufficiency. The data isn't definitive yet, but the mechanistic rationale is sound.
The grey matter volume associations in Macaron et al. (2021) were observed in cognitively healthy older adults, suggesting that adequate omega-3 status may support structural brain maintenance rather than reversing established decline. A prevention framing is more defensible than a treatment framing here, and I think that's the honest way to approach it.
For younger healthy adults eating a diet that includes oily fish 2, 3 times per week, the incremental benefit of supplementation is likely smaller. The evidence is thinner in this group, and I'd be overstating it to claim otherwise.
Omega-3 and attention: what the ADHD literature shows
There's a parallel literature on omega-3 and attention worth briefly addressing, it informs how to think about omega-3 and focus more broadly. D'Helft et al. (2022) reviewed the role of omega-3 PUFAs (and GLA) in ADHD, noting that omega-3 deficiency is consistently observed in ADHD populations and that supplementation studies show modest but real effects on attention and hyperactivity measures, particularly in children with confirmed low omega-3 status at baseline.
Effect sizes here are typically modest: standardised mean differences in the 0.3, 0.5 range in the better-controlled trials. Not dramatic, but not trivial either. Checa-Ros et al. (2021) add another layer by examining gut microbiome interactions in ADHD, there may be indirect pathways through which omega-3 status influences neurotransmitter availability via the gut-brain axis, though this is mechanistic territory and the human intervention data is limited.
If you're interested in other evidence-based approaches to focus and attention, the l-theanine and caffeine piece covers a different mechanistic pathway with some solid acute-effect data.
How omega-3 fits alongside other brain-relevant ingredients
DHA doesn't operate in isolation, and the cognitive performance picture involves multiple converging factors. A few ingredients worth understanding alongside omega-3:
Lion's mane mushroom
There's genuine interest in lion's mane for nerve growth factor (NGF) stimulation. The human trial data is limited, a small Japanese RCT showed some cognitive score improvements in older adults with mild cognitive impairment, but the mechanistic story is interesting. I've written a more detailed breakdown of the lion's mane benefits evidence if you want to go deeper.
Aged garlic extract
The research on aged garlic extract benefits includes some data on cerebrovascular circulation and oxidative stress markers, both of which are relevant to brain health. Large-scale human trials remain limited, so I'd frame it as supporting evidence rather than established fact.
Pine bark extract and grape seed extract
Both contain oligomeric proanthocyanidins that may support cerebrovascular function through nitric oxide pathways. Large-scale human RCTs in healthy adults are limited for both ingredients.
Frequently asked questions
How much omega-3 do I actually need for brain health?
Most RCTs showing structural or connectivity effects used 1,000, 2,000 mg combined EPA+DHA daily, with DHA making up at least 500 mg of that. Derbyshire (2018) notes the most consistent effects appear in populations with low baseline omega-3 status, so dietary context matters. If you eat oily fish regularly, your needs from supplementation are lower.
Is algal DHA as effective as fish oil for the brain?
Bioavailability studies show comparable absorption between algal DHA and fish-derived DHA. Fish accumulate DHA by eating algae, algal oil simply removes the middleman. It also sidesteps the oxidation and contamination concerns that affect lower-quality fish oils, and it's suitable if you don't eat fish. Calder (2017) covers DHA sources and metabolism in detail.
Will omega-3 supplements improve my memory or focus?
In healthy younger adults with adequate dietary omega-3 intake, the evidence for acute cognitive effects is thin and I'd be overstating it to claim otherwise. The stronger signal is in older adults, people with low baseline DHA status, and those with attention difficulties. Talukdar et al. (2020) found meaningful connectivity differences linked to omega-3 status, but this was observational data.
Does it matter whether I take EPA or DHA for cognitive support?
For brain-specific outcomes, DHA is the more relevant molecule. It accumulates preferentially in neural tissue and is the primary structural omega-3 in the brain. EPA crosses the blood-brain barrier less readily and is largely oxidised for energy rather than incorporated into membranes. Deckelbaum et al. (2021) make this distinction clearly and argue the two fatty acids should be evaluated separately.
How long does it take for omega-3 supplementation to affect brain DHA levels?
Red blood cell DHA levels, a commonly used biomarker, typically take 8, 12 weeks of consistent supplementation to plateau. Brain tissue incorporation is slower still and harder to measure non-invasively. Most RCTs run for at least 12 weeks; studies showing structural brain changes have typically run 6, 24 months. Macaron et al. (2021) reviewed longer-term associations in this context.
Are omega-3 supplements safe to take alongside other supplements?
For most people, yes. At doses above 3,000 mg EPA+DHA daily there is a theoretical platelet aggregation consideration, though the clinical significance at typical supplementation doses is low. Lucke-Wold et al. (2025) review omega-3 safety in the context of brain injury research, noting a generally favourable safety profile at standard doses.
My honest take
I built KōJō around the principle that you should be able to read exactly what I read before putting something in the formula. With DHA, the case is stronger than with most ingredients, but it's not the slam-dunk the marketing often implies.
The structural argument is solid. DHA is genuinely a major constituent of brain tissue, and the observational data linking omega-3 status to grey matter volume and functional connectivity is consistent enough to take seriously. The intervention data in healthy younger adults is thinner. If you're eating salmon three times a week and your omega-3 index is already high, the marginal benefit of a DHA supplement is probably small.
The evidence strikes me as most compelling for three groups: people who eat little or no oily fish (a large proportion of the UK population), older adults where DHA status tends to decline, and women at midlife where the interaction with oestrogen decline may matter, as Minihane (2025) explore in some depth.
I chose algal DHA over fish oil for the formula for practical reasons: better oxidative stability, no fishy aftertaste, no heavy metal concerns, and the same bioavailability. The form matters as much as the dose.
One thing I'd push back on in the broader omega-3 conversation: the idea that this is a nootropic in the acute, you'll-feel-it-today sense. It isn't. It's a structural nutrient that operates over months and years. If you're looking for that kind of immediate effect, the l-theanine and caffeine literature is more relevant. DHA is more like maintaining the hardware than running a performance programme on it.
I take it daily. Not because I expect to notice something tomorrow, but because the long-term structural case is strong enough that I don't want to be deficient over a decade.
This article is for informational purposes only and does not constitute medical advice.
References (12 studies)
- Minihane (2025), Omega-3 fatty acids, brain health and the menopause. PMID 40444522.
- Macaron et al. (2021), Associations of Omega-3 fatty acids with brain morphology and volume in cognitively healthy older adults: A narrative review. PMID 33607289.
- Talukdar et al. (2020), Nutrient biomarkers shape individual differences in functional brain connectivity: Evidence from omega-3 PUFAs. PMID 30556225.
- Derbyshire (2018), Brain Health across the Lifespan: A Systematic Review on the Role of Omega-3 Fatty Acid Supplements. PMID 30111738.
- Calder (2017), Docosahexaenoic Acid. PMID 27842299.
- Madore et al. (2020), Essential omega-3 fatty acids tune microglial phagocytosis of synaptic elements in the mouse developing brain. PMID 33257673.
- Deckelbaum et al. (2021), Editorial: Is it time to separate EPA from DHA when using omega-3 fatty acids to protect heart and brain? PMID 32028319.
- Paduchová et al. (2021), The Effect of Omega-3 Fatty Acids on Thromboxane, Brain-Derived Neurotrophic Factor, Homocysteine, and Vitamin D in Depression. PMID 33801688.
- D'Helft et al. (2022), Relevance of ω-6 GLA Added to ω-3 PUFAs Supplements for ADHD: A Narrative Review. PMID 36014778.
- Checa-Ros et al. (2021), Current Evidence on the Role of the Gut Microbiome in ADHD Pathophysiology and Therapeutic Implications. PMID 33467150.
- Lucke-Wold et al. (2025), Supplement and nutraceutical therapy in traumatic brain injury. PMID 40440029.
- Tseng et al. (2023), Omega-3 polyunsaturated fatty acids in sarcopenia management: A network meta-analysis of randomized controlled trials. PMID 37442370.
Photo via Unsplash
